COLLPLANT HOLDINGS LTD Financials Collplant Holdings Ltd TEL AVIV STOCK EXCHANGE
Equities
CLGN
IL0004960188
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - ILa | -.--% |
|
-14.91% | -.--% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 106.6 | 227.5 | 540.8 | 328 | 263.5 | 251.4 | - | - |
| Enterprise Value (EV) 1 | 106.6 | 227.5 | 540.8 | 328 | 263.5 | 251.4 | 251.4 | 251.4 |
| P/E ratio | -2.56 x | -12.8 x | 818 x | -5.46 x | -10.3 x | -4.14 x | -10.3 x | -147 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.8 x | 11.1 x | - | 307 x | 6.48 x | 23.9 x | 4.66 x | 3.11 x |
| EV / Revenue | 12.8 x | 11.1 x | - | 307 x | 6.48 x | 23.9 x | 4.66 x | 3.11 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 5,421 | 6,573 | 10,692 | 11,168 | 11,453 | 11,453 | - | - |
| Reference price 2 | 5.700 | 10.77 | 16.36 | 8.350 | 6.390 | 5.880 | 5.880 | 5.880 |
| Announcement Date | 4/1/20 | 3/26/21 | 3/24/22 | 3/29/23 | 4/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.346 | 20.45 | - | 1.069 | 40.64 | 10.53 | 53.98 | 80.75 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -27.48 | -18.65 | - | -61.14 | -27.86 | -61.32 | -24.78 | -1.974 |
| Operating Margin | -329.21% | -91.23% | - | -5,718.08% | -68.55% | -582.15% | -45.91% | -2.44% |
| Earnings before Tax (EBT) 1 | -40.2 | -19.24 | - | -60.53 | -26.03 | -60.56 | -24.48 | -1.709 |
| Net income 1 | -40.2 | -19.24 | 0.7649 | -60.53 | -26.03 | -60.56 | -24.48 | -1.709 |
| Net margin | -481.62% | -94.09% | - | -5,660.56% | -64.05% | -574.87% | -45.35% | -2.12% |
| EPS 2 | -2.230 | -0.8400 | 0.0200 | -1.530 | -0.6200 | -1.420 | -0.5700 | -0.0400 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/1/20 | 3/26/21 | 3/24/22 | 3/29/23 | 4/4/24 | - | - | - |
1ILS in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.4322 | - | 0.2074 | 1.61 | 38.64 | 0.1584 | 1.109 | 2.391 | 2.573 | 2.726 | 2.845 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.553 | - | -16.72 | -13.09 | 21.54 | -16.95 | -18.8 | -15.01 | -15.18 | -15.4 | -15.72 |
| Operating Margin | -2,210% | - | -8,062.21% | -812.7% | 55.74% | -10,701.98% | -1,694.99% | -627.88% | -590.16% | -565.16% | -552.75% |
| Earnings before Tax (EBT) 1 | -9.5 | - | -15.74 | -13.82 | 21.86 | -16.12 | -17.39 | -14.76 | -14.97 | -15.23 | -15.59 |
| Net income 1 | -9.5 | -14.88 | -15.74 | -13.82 | 21.86 | -16.12 | -17.39 | -14.76 | -14.97 | -15.23 | -15.59 |
| Net margin | -2,197.86% | - | -7,588.07% | -857.97% | 56.58% | -10,178.74% | -1,568.23% | -617.45% | -581.91% | -558.74% | -548.04% |
| EPS 2 | -0.2900 | -0.4000 | -0.3900 | -0.3300 | 0.4900 | -0.3800 | -0.4200 | -0.3500 | -0.3500 | -0.3600 | -0.3700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/18/21 | 12/1/22 | 3/29/23 | 5/24/23 | 8/24/23 | 11/29/23 | 4/4/24 | - | - | - | - |
1ILS in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 4/1/20 | 3/26/21 | 3/24/22 | 3/29/23 | 4/4/24 | - | - | - |
1ILS in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.88
USD
Average target price
11
USD
Spread / Average Target
+87.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.76% | 909M | |
| -19.12% | 129M | |
| +6.78% | 60.67M | |
| +2.99% | 53.19M |
- Stock Market
- Equities
- CLGN Stock
- CLGN Stock
- Financials Collplant Holdings Ltd
